)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
STENOCARE
STENOCARE (STENO) investor relations material
STENOCARE Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Net sales in Q2 2026 reached 3,997 kDKK, up 133% year-over-year and 33% sequentially from Q1 2026, driven by strong Danish market performance.
EBITDA was positive at 56 kDKK, marking the fifth consecutive quarter of positive EBITDA.
The legal merger with CannGros ApS was completed, with full operational integration and no additional costs.
Cash flow from operating activities was positive at 1,559 kDKK, with a cash position of 1,735 kDKK at quarter-end.
Progress continued in France toward a permanent national medical cannabis program, positioning the company for future market entry.
Financial highlights
Net sales for Q2 2026: 3,997 kDKK (Q2 2025: 1,719 kDKK); H1 2026: 7,000 kDKK (H1 2025: 2,500 kDKK).
EBITDA for Q2 2026: 56 kDKK (Q2 2025: 19 kDKK); H1 2026: 117 kDKK.
Net result for Q2 2026: -423 kDKK (Q2 2025: -146 kDKK); H1 2026: -882 kDKK.
Shareholders’ equity at June 30, 2026: 8,591 kDKK (June 30, 2025: 2,287 kDKK).
Cash at bank at quarter-end: 1,735 kDKK (Q2 2025: 4,870 kDKK).
Outlook and guidance
Continued focus on growth in established markets and readiness for new regulated medical cannabis markets, especially France.
Regulatory developments in France are expected to open significant opportunities for future sales.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from STENOCARE
- Q1 2026 saw 284% sales growth, positive EBITDA, and full CannGros integration.STENO
Q1 2026 - Record sales and positive EBITDA achieved in 2025, with market share boosted by CannGros acquisition.STENOQ4 2025
- Record sales and positive EBITDA mark a strong Q3 2025, with growth and cost discipline.STENOQ3 2025
- Achieved break-even and 131% sales growth in Q2 2025, with strong regulatory and market momentum.STENOQ2 2025
- Sales and liquidity under pressure as trading focus and new launches aim to drive recovery.STENOQ3 2024
- Sales declined and guidance was lowered, but financial stability and product innovation advanced.STENOQ2 2024
- TO2 Warrant share issue funds expansion, product launches, and break-even targets for 2024.STENOInvestor update
- Stenocare pivots to trading, cuts costs, and launches ASTRUM 10-10 amid regulatory wins.STENOQ1 2025
- STENOCARE pivots to trading, cuts costs, and secures new markets after Danish legalisation.STENOQ4 2024
Next STENOCARE earnings date
Q3 202629 Oct, 2026
STENOCARE
Next STENOCARE earnings date
Q3 202629 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage